In the latest of a string a partnerships forged this year, Daiichi Sankyo is teaming up with Sanofi's Japanese unit to launch Squarekids subcutaneous injection syringe, a tetravalent vaccine for the prevention of diphtheria, pertussis, tetanus and polio.
In the jockeying for share in the brand-new market for the specialized PCSK9 cholesterol-lowering meds, Amgen has picked up an edge over Sanofi by nailing a formulary exclusive with CVS. To get that preferred spot, Amgen has again agreed to tie the price of the drug to its effectiveness.
AstraZeneca and Sanofi have exchanged 210,000 compounds from their respective libraries in a no-cash, no-strings-attached deal. The agreement gives scientists at both companies free rein to research and develop compounds shared by the other, without having to pay fees or steer clear of certain therapeutic areas.
When it comes to publishing a full set of trial data on new drugs, the biopharma industry overall has a poor record on transparency, according to a new report from a bioethics watchdog group. And some companies--like Sanofi and Gilead--fall well below the "legal and ethical" standards on this score.
This week at the World Vaccines Congress in Spain, Sanofi Pasteur announced that in collaboration with the University of Georgia it has developed a candidate flu vaccine through genetic sequencing of many flu viruses. The vaccine, dubbed Cobra, is designed to protect against multiple strains over several years using common sequences the strains share.
Sanofi is accused of stalling its multiple sclerosis drug Lemtrada to avoid paying out $708 million to rights holders as required by its 2011 deal to buy Genzyme. As part of that deal, the French drugmaker agreed to a series of milestone payments, including an FDA approval deadline for Lemtrada.
For several months, Sanofi's new CEO Olivier Brandicourt has indicated that one part of his turnaround plan for the French drugmaker would involve significant changes in manufacturing to make it more efficient. And while the CEO told investors Friday that he would be looking for $1.6 billion in cost cuts in the next three years, and that some would come from a "reshape" of the manufacturing network, he was short on details about how that might play out.
Back in 2011, when Sanofi acquired Genzyme for about $20 billion, it promised the company's shareholders up to $3.8 billion more tied to the then-in-development multiple sclerosis treatment Lemtrada. Things went awry in 2013 when the FDA rejected the therapy, but a new shareholder lawsuit claims that's just what Sanofi wanted.
If Sanofi CEO Olivier Brandicourt wanted to win over analysts with Friday's pronouncements about the company's future, he must be disappointed now. A slew of investment firms cut their price targets and several downgraded the shares, as the French drugmaker's strategy for future growth was outweighed by warnings about stagnant earnings for the next few years.
Olivier Brandicourt got his first shot at Sanofi's lead role in an annual investor day, and the reviews are not good. Brandicourt had a tough message to sell. The company's diabetes franchise is getting hammered, with the all-important Lantus business weakening, which means that R&D as well as SG&A are going to eat up a higher percentage of revenue for at least a couple of years.